文献速递糖尿病

妊娠期使用二甲双胍对婴儿早期营养状况的系统评价

Metformin Use During Pregnancy and Early‐Life Nutritional Status: A Systematic Review of Randomized Clinical Trials
RSS 订阅 · Diabetes, Obesity and Metabolism · 2026-10-27

本系统评价检索 PubMed 和 Scopus 建库至 2026 年 5 月的随机对照试验,比较妊娠期二甲双胍与安慰剂或常规治疗对婴儿出生至 12 个月营养状况及肥胖相关结局的影响。共纳入 6 项随机对照试验的 8 篇发表文献。结果显示二甲双胍与出生体重及其他人体测量指标的差异并不一致,且无研究直接测量婴儿肥胖程度。

要点

  • 现有证据未一致支持产前二甲双胍暴露影响婴儿早期人体测量指标。
  • 产后随访数据有限,缺少婴儿体脂直接测量,难以评估代谢编程。
  • 未来研究应开展标准化纵向体成分评估。

核心结论

  • 现有证据未一致支持产前二甲双胍暴露对早期婴儿人体测量学产生影响。
  • 有限的产后数据和缺乏肥胖程度测量,限制了对产后生长及早期代谢编程的结论。

研究设计与样本

  • 系统评价检索 PubMed 和 Scopus 建库至 2026 年 5 月,纳入比较妊娠期二甲双胍与安慰剂或常规治疗的随机对照试验。
  • 共纳入 6 项随机对照试验的 8 篇发表文献,结局时限为出生至 12 个月。

主要发现

  • 出生体重和出生体型分类是最常报告的结局指标。
  • 二甲双胍与出生体重或其他人体测量指标的差异并不一致。
  • 一项试验报告出生体重更低,两项试验报告大于胎龄儿或巨大儿更少。
  • 无研究评估婴儿肥胖程度的直接测量指标。

临床怎么用

  • 目前证据不足以支持仅因担心婴儿早期生长而改变妊娠期二甲双胍使用决策。
  • 临床随访可继续关注常规人体测量,但应意识到缺少体脂数据。

局限性

  • 产后随访资料有限,缺少婴儿肥胖程度直接测量。
  • 各研究报告的结局指标不一致,限制定量合并。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT Background and Aims Metformin is increasingly used to treat gestational diabetes mellitus and other insulin-resistant conditions during pregnancy. Because it crosses the placenta, concerns remain regarding its potential effects on offspring growth and metabolic programming. This systematic review evaluated the effects of prenatal metformin exposure on infant nutritional status and adiposity during the first year of life. Methods PubMed and Scopus were searched from inception through May 2026 for randomized controlled trials comparing metformin with placebo or standard care during pregnancy. Eligible studies reported infant nutritional status or adiposity-related outcomes from birth to 12 months. Risk of bias was assessed, and results were synthesized narratively. Results Eight publications from six randomized controlled trials were included. Birthweight and birth size classifications were the most frequently reported outcomes. Metformin was not consistently associated with differences in birthweight or other anthropometric measures. One trial reported lower birthweight, while two reported fewer large-for-gestational-age or macrosomic infants. No study assessed direct measures of infant adiposity. Conclusions Current evidence does not consistently support an effect of prenatal metformin exposure on early infant anthropometry. Limited postnatal data and absent adiposity measures limit conclusions regarding postnatal growth and early metabolic programming and support standardized longitudinal body composition assessment.

来源:Diabetes, Obesity and Metabolism,查看原文。版权归原作者所有。

引用

  1. Diabetes, Obesity and Metabolism:Metformin Use During Pregnancy and Early‐Life Nutritional Status: A Systematic Review of Randomized Clinical Trials

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。